

15.00

OPENING REMARKS**Fruchart J.-C.** (Lille, France)**Paoletti R.** (Milan, Italy)**Staels B.** (Lille, France)**PLENARY LECTURES**Chairperson: **Paoletti R.** (Milan, Italy)

hour:

abstract bk.
page ref.:

15.30

PPAR-alpha, METABOLIC DISEASES AND ATHEROSCLEROSIS

Fruchart J.-C. (Lille, France)**1**

16.15

REGULATION OF ADIPOGENESIS AND ENERGY METABOLISM THROUGH
PPAR-gamma AND PGC-1**Spiegelman B.M.**, Rosen E., Puigserver P., Yoon C., Wu Z. (Boston, USA)**1**

17.00

End of the Session

Plenary Session

**STRUCTURE, FUNCTION AND
MOLECULAR MECHANISMS OF PPAR ACTION**

Chairpersons: **Fruchart J.-C.** (Lille, France)
O'Rahilly S. (Cambridge, UK)

hour:		abstract bk. page ref.:
9.30	ROLES OF PPAR IN ENERGY HOMEOSTASIS AND EPIDERMIS DIFFERENTIATION Wahli W. , Michalik L., Kersten S., Tan N.S., Desvergne B. (Lausanne, Switzerland)	1
10.00	PPARs-MOLECULAR GENETICS AND FUNCTIONAL GENOMICS Moller D.E. (Rahway, USA)	1
10.30	MOLECULAR MECHANISM OF PPAR-gamma ACTION IN MACROPHAGES Chawla A. , Lee C.H., Barak Y., Liao D., Evans R.M. (La Jolla, USA)	2
11.00	<i>Break</i>	
11.30	DESIGN STRUCTURE AND FUNCTION OF NOVEL PPAR LIGANDS Willson T.M. (Research Triangle Park, USA)	2
12.00	<i>End of the Session</i>	

Workshop

INFLAMMATION AND ATHEROSCLEROSIS

Chairpersons: **Staels B.** (Lille, France)
Tremoli E. (Milan, Italy)

hour:		abstract bk. page ref.:
14.00	MOLECULAR MECHANISMS OF THE NF-kappaB / PPARalpha CROSS-TALK Delerive P. , De Bosscher K., Vanden Berghe W., Fruchart J.-C., Haegeman G., Staels B. (Lille, France and Gent, Belgium)	2
14.20	PPARs AND ATHEROGENESIS: MEDIATORS OR MODULATORS OF THE INFLAMMATORY RESPONSE IN THE VESSEL WALL? Marx N. (Ulm, Germany)	2
14.40	EFFECTS OF THIAZOLIDINEDIONES ON VASCULAR REACTIVITY AND ENDOTHELIAL DYSFUNCTION Horton E.S. , Caballero A.E., Saouaf R., Veves A. (Boston, USA)	3
15.00	PPAR-gamma LIGANDS INDUCE VASCULAR SMOOTH MUSCLE CELL APOPTOSIS Bishop-Bailey D. , Hla T., Warner T. (London, UK and Farmington, USA)	3
15.15	OXIDIZED PHOSPHOLIPIDS INHIBIT CYCLOOXYGENASE-2 IN HUMAN MACROPHAGES VIA A NF-kappaB-DEPENDENT MECHANISM Eligini S., Brambilla M., Banfi C., Camera M., Sironi L., Barbieri S.S., Tremoli E., Colli S. (Milan, Italy)	3
15.30	C-36 FRAGMENT OF alpha-1-ANTITRYPSIN ACTIVATES PPAR-alpha AND PPAR-gamma IN PRIMARY HUMAN MONOCYTES AND IS PRESENT IN ATHEROSCLEROTIC PLAQUES Dichtl W. , Moraga F., Ares M.P.S., Crisby M., Nilsson J., Lindgren S., Janciauskiene S. (Innsbruck, Austria and Malmö, Sweden)	3
15.45	PPAR-gamma - A MEDIATOR OF LEUKOCYTE/MACROPHAGE DYSFUNCTION IN SEPSIS von Knethen A. , Tautenhahn A., Brüne B. (Erlangen, Germany) <i>WITHDRAWN</i>	4
16.00	<i>End of the Session</i>	
16.00	<i>Break</i>	

Symposium

**PPAR -gamma AND -alpha AS
THERAPEUTIC TARGETS IN DIABETES**Chairperson: **Hoogwerf B.J.** (Cleveland, USA)

hour:		abstract bk. page ref.:
16.30	OPENING REMARKS	
16.35	ACTIVATION OF HUMAN PPAR SUBTYPES BY PIOGLITAZONE Kimura H. (Osaka, Japan)	4
17.10	CLINICAL SIGNIFICANCE OF PPAR-gamma AND -alpha AGONISM IN DISEASE: AN UPDATE ON PIOGLITAZONE RESEARCH Staels B. (Lille, France)	4
17.45	PANEL DISCUSSION	
18.25	CLOSING REMARKS	
18.30	<i>End of the Session</i>	

Supported by an unrestricted educational grant provided by: TAKEDA CHEMICAL INDUSTRIES, LTD.

Workshop

PPARs ACTIVATION BY NATURAL AND SYNTHETIC LIGANDS

Chairpersons: **Gustafsson J.-Å.** (Huddinge, Sweden)
Willson T.M. (Research Triangle Park, USA)

hour:		abstract bk. page ref.:
14.00	ON THE ROLE OF LXR-alpha IN LIPID ACCUMULATION IN ADIPOCYTES DURING DIFFERENTIATION Gustafsson J.-Å. , Schuster G., Nebb H. (Huddinge, Sweden and Oslo, Norway)	4
14.20	PPARs AS REGULATORS OF LIPID METABOLISM THROUGH THE CONTROL OF LONG AND VERY LONG CHAIN FATTY ACID PEROXISOMAL beta-OXIDATION Nicolas-Francès V., Hansmannel F., Clémencet M.-C., Osumi T., Latruffe N. (Dijon, France and Hyogo, Japan)	5
14.35	RATIONAL DESIGN OF NOVEL PPAR-gamma MODULATORS DERIVED FROM THE POTENT AGONIST GI262570 Cobb J.E. , Cooper J.P., Shearer B.G., Lambert M.H., Willson T.M., Blanchard S.G., Shenk J., Plunket K., Nolte R.T., Leesnitzer L.M., Miller A.B., (Research Triangle Park, USA)	5
14.50	LXR-alpha IS A TARGET GENE FOR PPAR-gamma IN ADIPOCYTES Juvet L.K., Mæhle S., Dalen K.T., Tobin K.A.R., Hollung K., Haugen F., Jacinto S., Gustafsson J.A., Bamberg K., Nebb H.I. (Oslo, Norway, and Mölndal, Huddinge, Sweden)	5
15.05	A NEW CLASS OF ANTIOXIDANT THIAZOLIDINEDIONES Pershadsingh H.A. , Venkatraman M.S., Avery M.A., Benson S.C., Kurtz T.W. (Bakersfield, USA)	5
15.20	PROPIONIC ACID INDUCES THE EXPRESSION OF NUCLEAR RECEPTORS PPAR-alpha: A POTENTIAL EFFECT ON HDL LEVEL Naruszewicz M. , Zapolska-Downar D., Kaczmarczyk M. (Szczecin, Poland)	6
15.35	LIPID MODULATING AND ANTIDIABETIC POTENCY OF THE PPAR-alpha ACTIVATORS BM 17.0744 AND BEZAFIBRATE Pill J. , Nakayama M., Bodkin N.L., Hansen B.C., Meyer K. (Mannheim, Germany and Baltimore, USA)	6
15.50	ROLE OF THE ENDOGENOUS PPAR-gamma AGONIST 15-delta12,14-PGJ2 IN THE PATHOPHYSIOLOGY OF ALZHEIMER DISEASE Cipollone F. , Zuliani G., Marini M., Iezzi A., Fazia M., Pini B., De Cesare D., Cuccurullo F., Fellin R., Mezzetti A. (Chieti and Ferrara, Italy)	6
16.05	<i>End of the Session</i>	
16.05	<i>Break</i>	

Workshop

PPARs: MOLECULAR MECHANISMS AND CROSSTALK WITH OTHER SIGNALLING PATHWAYS

Chairpersons: **Chawla A.** (La Jolla, USA)
Spiegelman B.M. (Boston, USA)

hour:		abstract bk. page ref.:
16.30	PPAR-gamma, CELL GROWTH AND SIGNAL TRANSDUCTION Spiegelman B.M. (Boston, USA)	6
16.50	THE ROLE OF FATTY ACID BINDING PROTEINS IN FATTY ACID AND DRUG SIGNALING TO PPARs Spener F. (Münster, Germany)	7
17.05	TUMOR SUPPRESSOR AND ANTI-INFLAMMATORY ACTIONS OF PPAR-gamma AGONISTS ARE MEDIATED VIA UPREGULATION OF PTEN Patel L., Pass I., Coxon P., Downes C.P., Smith S.A., Macphee C.H. (Harlow and Dundee, UK)	7
17.20	THE ORPHAN NUCLEAR RECEPTOR SHP FUNCTIONS AS A POSITIVE REGULATOR OF PPAR-gamma2 Nishizawa H. , Yamagata K., Takahashi M., Kihara S., Yamashita S., Nishigori H., Tomura H., Takeda J., Funahashi T., Matuzawa Y. (Osaka and Gunma, Japan)	7
17.35	REGULATION OF PPAR-delta - MEDIATED TRANS-ACTIVATION Krogsdam A.M. , Rasmussen T.H., Holst D., Kratchmarova I., Dam I., Hansen J.B., Jørgensen C., Kristiansen K. (Odense, Denmark)	7
17.50	METABOLIC CONTROL OF THE UNCOUPLING PROTEIN-3 (UCP3) GENE EXPRESSION IN SKELETAL MUSCLE: PPAR-alpha ACTIVATES THE UCP3 GENE PROMOTER THROUGH A PROXIMAL MULTI-HORMONAL RESPONSE ELEMENT Solanes G., Pedraza N., Iglesias R., Giralt M., Villarroya F. (Barcelona, Spain)	8
18.05	PPAR-gamma ACTIVATION-INDUCED REGULATION OF PROLIFERATION AND DIFFERENTIATION OF ENDOTHELIAL CELL INVOLVE MODIFICATION OF THE Jagged/Notch EXPRESSION Dembirńska-Kieć A. , Polus A., Piatkowska E., Lapicka K. (Kraków, Poland)	8
18.20	ROLE FOR PPAR-beta IN HEPATIC STELLATE CELL TRANSITION; IMPLICATIONS FOR WOUND REPAIR AND FIBROGENESIS Hellemans K. , Dittié, A., Knorr A., Rombouts K., Michalik L., Wahli W., Geerts A. (Brussels, Belgium, Wuppertal, Germany and Lausanne, Switzerland)	8
18.35	<i>End of the Session</i>	

Workshop

PPARs AND NOVEL TARGET GENES

Chairpersons: **Kliwer S.** (Research Triangle Park, USA)
Moller D.E. (Rahway, USA)

hour:		abstract bk. page ref.:
14.00	IDENTIFICATION OF GENES REGULATED BY PPAR-gamma Way J., Harrington W., Brown K., Mansfield T., Willson T., Kliwer S. (Research Triangle Park and New Haven, USA)	8
14.20	THE REGULATION OF UCP-2 EXPRESSION BY FATTY ACIDS IN CULTURED HUMAN MUSCLE CELLS INVOLVES THE NUCLEAR RECEPTOR PPAR-beta Chevillotte E. , Rieusset J., Roques M., Desage M., Vidal H. (Lyon, France)	9
14.35	THE GENE ENCODING THE ACYL-CoA BINDING PROTEIN IS ACTIVATED BY PPAR-alpha AND - gamma THROUGH AN INTRONIC PPRE OVERLAPPING AN ALTERNATIVE SPLICE DONOR SITE Helledie T., Boysen M.S., Jensen S.S., Larsen J.N., Larsen L.K., Kristiansen K., Mandrup S. (Odense, Denmark)	9
14.50	BOTH CONSTITUTIVE AND FENOFIBRATE-INDUCIBLE MOUSE ALDR mRNA EXPRESSION IS REGULATED BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR alpha Berger J. , Korosec T., Weinhofer I., Forss-Petter S., Netik A. (Vienna, Austria)	9
15.05	SELECTIVE INCREASES IN HEPATIC PYRUVATE DEHYDROGENASE KINASE (PDK) ISOFORM EXPRESSION ELICITED BY HYPERTHYROIDISM AND PEROXISOME-PROLIFERATOR ACTIVATED RECEPTOR alpha (PPAR-alpha): THE RETINOID X RECEPTOR (RXR) AS A COMMON FEATURE? Holness M.J. , Smith N.D., Lall H.S., Sugden M.C. (London, UK)	9
15.20	ACTIVATION OF PEROXISOME-PROLIFERATOR ACTIVATED RECEPTOR alpha (PPAR-alpha) BY WY14643 SELECTIVELY INCREASES PYRUVATE DEHYDROGENASE KINASE 4 EXPRESSION IN RAT PANCREATIC ISLETS Sugden M.C. , Bulmer K., Holness M.J. (London, UK)	10
15.35	GENE EXPRESSION PROFILING OF PPAR-alpha NULL MICE DURING FASTING BY OLIGONUCLEOTIDE MICROARRAY Kersten S. , Escher P., Jatkoe T., Mandard S., Genolet R., Rojas-Caro S., Wang Y., Madore S., Desvergne B., Tafuri S., Wahli W. (Lausanne, Switzerland, Ann Arbor, USA and Wageningen, The Netherlands)	10
15.50	<i>End of the Session</i>	
15.50	<i>Break</i>	

Workshop

ANIMAL MODELS TO STUDY PPAR FUNCTIONS

Chairpersons: **Desvergne B.** (Lausanne, Switzerland)
Gonzalez F.J. (Bethesda, USA)

hour:		abstract bk. page ref.:
16.30	ANIMAL MODELS TO STUDY PPAR FUNCTIONS Gonzalez F.J. , Akiyama T., Gavrilova O., Matsusue K., Nicol C., Peters J.M., Reitman M.L. (Bethesda, USA)	10
16.50	IDENTIFICATION OF GENES INVOLVED IN THE DEVELOPMENT OF METABOLIC CARDIOMYOPATHIES Gürtl B. , Nöhammer C., Kratky D., Tessaro B., Zechner R., Höfler G. (Graz, Austria)	10
17.05	EFFECTS OF GONADECTOMY, HYPOPHYSECTOMY AND GROWTH HORMONE ON PPAR α mRNA IN RAT LIVER Jalouli M., Carlsson L., Lindén D., Edén S., Oscarsson J. (Göteborg, Sweden)	11
17.20	PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR α : A NEW PHARMACOLOGICAL TARGET FOR STROKE? Deplanque D., Gelé P., Six I., Bouly M., Staels B., Fruchart J.C., Duriez P. , Bordet R. (Lille, France)	11
17.35	PPAR- α AND PPAR- β FUNCTIONS DURING ADULT MURIN SKIN REGENERATION Michalik L. , Desvergne B., Basu-Modak S., Escher P., Rieusset J., Tan N.S., Peters J.M., Kaya G., Gonzalez F.J., Zakany J., Metzger D., Chambon P., Duboule D., Wahli W. (Lausanne and Geneva, Switzerland)	11
17.50	THE GASTRINE RELEASING EFFECT OF PPAR α LIGANDS IN RATS Waldum H.L. , Martinsen T.C., Bakke I., Sandvik A.K. (Trondheim, Norway)	11
18.05	PPAR- α IS REQUIRED FOR THE <i>IN VIVO</i> REGULATION OF HUMAN APOA-I GENE EXPRESSION BY FIBRATES Duez H. , Poulain P., Fiévet C., Bertrand K., Fruchart J.C., Staels B. (Lille and Loos, France)	12
18.20	INCREASED 15-DEOXY-DELTA12, 14-PGJ2 IN URINE OF OBESE ZUCKER RATS Thévenon C., Géloën A. , Lagarde M. (Lyon and Villeurbanne, France)	12
18.35	<i>End of the Session</i>	

Plenary Session

PPAR-alpha: FROM BASIC SCIENCE TO CLINICAL APPLICATIONS

Chairpersons: **Taskinen M.-R.** (Helsinki, Finland)
Sirtori C.R. (Milan, Italy)

hour:		abstract bk. page ref.:
9.30	PPAR-alpha, LIPOPROTEIN METABOLISM AND ATHEROSCLEROSIS Fruchart J.-C. (Lille, France)	12
10.00	PPAR-alpha AND THE METABOLIC SYNDROME Staels B. (Lille, France)	12
10.30	PPAR-alpha IN ATHEROSCLEROSIS Plutzky J. , Marx N., Mackman N., Collins T., Libby P., Perrey S., Ziouzenkova O. (La Jolla, USA, Ulm, Germany and Boston, USA)	13
11.00	<i>Break</i>	
11.30	REGULATION OF CD36 BY PPAR-gamma: PRO OR ANTI-ATHEROGENIC? Gotto A.M. Jr., Febbraio M. , Han J., Nicholson A., Hajjar D.P., Silverstein R.L. (New York, USA)	13
12.00	VA-HIT AND OTHER CLINICAL TRIALS WITH FIBRATES Robins S.J. (Boston, USA)	13
12.30	<i>End of the Session</i>	

Workshop

LIPID AND LIPOPROTEIN METABOLISM AND ATHEROSCLEROSIS

Chairpersons: **Barter P.J.** (Adelaide, Australia)
Galli C. (Milan, Italy)

hour:		abstract bk. page ref.:
14.00	ANTI-INFLAMMATORY PROPERTIES OF HIGH DENSITY LIPOPROTEINS Barter P.J. (Adelaide, Australia)	13
14.20	ROLES FOR PPAR-alpha AND PPAR-beta IN EXPRESSION OF GENES CODING FOR CARDIAC FATTY ACID-HANDLING PROTEINS van der Lee K.A.J.M. , Willemsen P.H.M., Gilde A.J., van der Vusse G.J., van Bilsen M. (Maastricht, The Netherlands)	14
14.35	BILE ACID REGULATION OF HUMAN PPAR alpha GENE EXPRESSION IS MEDIATED BY THE FARNESOID-X RECEPTOR (FXR) Pineda Torra I. , Claudel T., Duval C., Fruchart J.-C., Staels B. (Lille, France)	14
14.50	EFFECTS OF FIBRATE ON STEROL REGULATORY ELEMENT BINDING PROTEINS AND LIPID SYNTHESIS Knight B. , Patel D., Wiggins D., Gibbons G. (London and Oxford, UK)	14
15.05	ASSOCIATION OF THE PPAR-alpha L162V MISSENSE MUTATION WITH CHOLESTEROL AND TRIGLYCERIDE CONTENTS OF LIPOPROTEIN SUBFRACTIONS Brisson D., Vohl M.C. , Perron P., Després J.P., Hudson T.J., Gaudet D. (Sainte-Foy, Canada and Cambridge, USA)	14
15.20	ACTIVATION OF PPAR-alpha IS NOT SUFFICIENT TO REDUCE PLASMA TRIACYLGLYCEROLS Madsen L. , Dyrøy E., Wergedahl H., Berge K., Tronstad K.J., Berge R.K. (Bergen, Norway)	15
15.35	INDUCTION OF MOUSE PLTP EXPRESSION BY FENOFIBRATE THROUGH A PPAR-alpha-DEPENDENT MECHANISM Bouly M. , Masson D., Gross B., Peters J.M., Fiévet C., Castro G., Gonzalez F.J., Fruchart J.C., Staels B., Lagrost L., Luc G. (Lille, France and Bethesda, USA)	15
15.50	EFFECTS OF CYTOKINES, STEROID HORMONES AND PPAR LIGANDS ON PAI-1 GENE EXPRESSION AND SYNTHESIS IN HUMAN ADIPOCYTES Pedersen S.B. , Gengsheng H., Bruun M., Richelsen B. (Aarhus, Denmark)	15
16.05	<i>End of the Session</i>	
16.05	<i>Break</i>	

Symposium

THE IMPORTANCE OF RAISING HDL: FROM PPAR-alpha TO CLINICAL IMPLICATIONS

Chairpersons: **Barter P.J.** (Adelaide, Australia)
Catapano A.L. (Milan, Italy)

hour:		abstract bk. page ref.:
16.30	THE LOW HDL SYNDROME: EPIDEMIOLOGY AND PREVALENCE Franceschini G. (Milan, Italy)	15
16.50	PPAR-alpha, FIBRATE AND HDL METABOLISM Fruchart J.-C. (Lille, France)	16
17.10	DIABETES: A GROWING CHD EPIDEMIC Hamsten A. , for the Diabetes Atherosclerosis Intervention Study Investigators (Stockholm, Sweden)	16
17.30	HDL-C AND CHD: LESSONS FROM THE STATIN TRIALS Sacks F.M. (Boston, USA)	16
17.50	HDL-C AND CHD: LESSONS FROM THE FIBRATE TRIALS Robins S.J. (Boston, USA)	13
18.10	LOW HDL-C AND CHD: TREATMENT TARGET AND NEW INTERNATIONAL EXPERT PANEL RECOMMENDATIONS Barter P.J. , on behalf of the International Expert Panel on HDL (Adelaide, Australia)	16
18.30	QUESTIONS AND ANSWERS	
18.40	<i>End of the Session</i>	

Supported by an unrestricted educational grant provided by: GROUPE FOURNIER

Workshop

ADIPOSE TISSUE, OBESITY, AND DIABETES

Chairpersons: **Farmer S.R.** (Boston, USA)
Kraegen E.W. (Sydney, Australia)

hour:		abstract bk. page ref.:
14.00	THE INFLUENCE OF PPARs ON MUSCLE LIPID METABOLISM AND INSULIN RESISTANCE Kraegen E.W. (Sydney, Australia)	17
14.20	PPAR-gamma IN ADIPOGENESIS AND INSULIN RESISTANCE Farmer S.R. , Hamm J.K., Park B.-H., Moldes M. (Boston, USA)	17
14.40	EFFECT OF THIAZOLIDINEDIONES ON THE EXPRESSION AND PLASMA LEVELS OF ADIPONECTIN, ANTI-ATHEROGENIC PROTEIN Maeda N. , Takahashi M., Hotta K., Shimomura I., Kihara S., Nakamura T., Funahashi T., Matsuzawa Y. (Osaka, Japan)	17
14.55	ROLE OF PPAR-alpha IN BROWN ADIPOSE TISSUE Giralt M. , Barberá M.J., Schlüter A., Pedraza N., Iglesias R., Villarroya F. (Barcelona, Spain)	17
15.10	FENOIBRATE PREVENTS AND REDUCES BODY WEIGHT GAIN AND ADIPOSITY IN DIET-INDUCED OBESE RATS Sabatino L., Lanni A., Moreno M., Giannino A., Contaldo F., Colantuoni V., Goglia F., Mancini F.P. (Benevento, Italy)	18
15.25	EXPRESSION OF PPAR-alpha TARGET GENES IMPROVES INSULIN ACTION AND REDUCES ADIPOSITY Berge R.K. , Madsen L., Guerre-Millo M., Berge K., Bergene E., Flint E.N., Sebokova E., Rustan A.C., Jensen J., Mandrup S., Kristiansen K., Klimes I., Staels B. (Bergen, Oslo, Norway, Paris, Lille, France, Bratislava, Slovak Republic and Odense, Denmark)	18
15.40	CONJUGATED LINOLEIC ACID FED MICE DEVELOP A LIPOATROPHIC DIABETES SYNDROME WHICH IS PARTIALLY IMPROVED BY THE PPAR-alpha GENE DISRUPTION Clement L., Poirier H., Niot I., Monnot M.C., Guerre-Millo M., Pineau T., Besnard P. (Dijon, Paris and Toulouse, France)	18
15.55	EFFECTS OF TROGLITAZONE AND METFORMIN ON GLUCOSE METABOLISM, PLASMA LEPTIN AND E-SELECTIN IN TYPE-2 DIABETES Kautzky-Willer A. , Wagner O.F., Georg P., Ludvik B., Waldhäusl W., Pacini G., Prager R. (Vienna, Austria and Padua, Italy)	18
15.55	<i>End of the Session</i>	
15.55	<i>Break</i>	

Workshop

CELL CYCLE AND CANCER

Chairpersons: **Reddy J.K.** (Chicago, USA)
Wu G.D. (Philadelphia, USA)

hour:		abstract bk. page ref.:
16.30	PEROXISOME PROLIFERATOR-INDUCED CARCINOGENESIS: PPARs, COACTIVATORS, AND TARGET GENES Reddy J.K. (Chicago, USA)	19
16.50	PPAR-ACTIVATING 3-THIA FATTY ACID INFLUENCES THE GROWTH POTENTIAL AND METABOLISM IN GLIOMA CELLS Tronstad K.J. , Berge K., Dyroy E., Madsen L., Berge R.K. (Bergen, Norway)	19
17.05	PPARs AND RXRs IN HUMAN NEUROBLASTOMA AND GLIOBLASTOMA CELL LINES. EFFECTS OF NATURAL AND SYNTHETIC LIGANDS Cimini A.M. , Cristiano L., Colafarina S., Miranda M., Cerù M.P. (L'Aquila, Italy)	19
17.20	TETRADECYLTHIOACETIC ACID INHIBITS GROWTH OF RAT GLIOMA CELLS <i>EX VIVO</i> AND <i>IN VIVO</i> VIA PPAR-DEPENDENT AND PPAR-INDIPENDENT PATHWAYS Berge K. , Tronstad K.J., Flindt E.N., Rasmussen T.H., Madsen L., Kristiansen K., Berge R.K. (Bergen, Norway)	19
17.35	PPAR-gamma MEDIATED APOPTOTIC CELL DEATH IN HUMAN AND RAT GLIOMA CELL LINES. A NEW THERAPEUTIC STRATEGY? Zander T. , Kraus J.A., Schlegel U., Feinstein D., Klockgether T., Heneka M.T. (Bonn, Germany and Chicago, USA)	20
17.50	15-DEOXYDELTA12, 14-PROSTAGLANDIN J2 ACTIVATES PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR gamma AND INDUCES TYPE II PROGRAMMED CELL DEATH OF HUMAN NEOUROBLASTOMA CELLS Rodway H.A. , Hunt A.N., Kohler J.A., Postle A.D., Lillycrop K.A. (Southampton, UK)	20
18.05	CHARACTERISATION OF THE CELL AND MOLECULAR MECHANISM OF ACTION OF PPAR-gamma IN PROSTATE CELLS Tatoud R. , Palmer C.N.A. (Dundee, UK)	20
18.20	ROLE OF PPAR-alpha IN COLONIC MALIGNANCY Jackson L.M. , Bennett A.J., Watson S., Wahli W., Hawkey C.J., (Nottingham, UK and Lausanne, Switzerland)	20
18.35	<i>End of the Session</i>	

Symposium

PPAR-delta: FUNCTION AND BIOLOGY

Chairpersons: **Wahli W.** (Lausanne, Switzerland)
Willson T.M. (Research Triangle Park, USA)

hour:		abstract bk. page ref.:
14.00	PPAR-beta IS REQUIRED FOR THE PROPER DEVELOPMENT OF MOUSE PLACENTA Desvergne B. , Nadra K., Basu-Modak S., Zakani J., Metzger D., Chambon P., Duboule D., Wahli W. (Lausanne, Switzerland)	21
14.30	SCREENING FOR FUNCTIONAL POLYMORPHISMS IN HUMAN PEROXYISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA (hPPARD) GENE Kannisto K. , Skogsberg J., Gagné E., Ehrenborg E. (Stockholm, Sweden)	21
14.45	ACTIVATION OF PPAR-delta INCREASES HDL CHOLESTEROL AND LOWERS SERUM TRIGLYCERIDES IN SPONTANEOUSLY OBESE, DYSLIPIDEMIC PRIMATES Oliver W. Jr. , Sternbach D., Bodkin N., Hansen B. (Research Triangle Park and Baltimore, USA)	21
15.15	PPAR-delta PROMOTES LIPID ACCUMULATION IN MACROPHAGES Vosper H., Patel L., Khoudoli G.A., Hill A., Macphee C.H., Pinto I., Smith S.A., Suckling K.E., Wolf C.R., Palmer C.N.A. (Dundee, UK)	21
15.30	CONCLUDING REMARKS	
16.00	<i>End of the Session</i>	

Plenary Session

PPAR-gamma: FROM BASIC SCIENCE TO CLINICAL APPLICATIONS

Chairpersons: **Spiegelman B.M.** (Boston, USA)
Wahli W. (Lausanne, Switzerland)

hour:		abstract bk. page ref.:
9.30	PPAR-gamma: A REGULATOR OF GROWTH AND DIFFERENTIATION Farmer S.R. , Morrison R.F., Moldes M. (Boston, USA)	22
10.00	REGULATION OF MACROPHAGE GENE EXPRESSION BY PPAR-gamma Glass C.K. , Ricote M., Li A., Huang J., Welch J., Willson T., Brown K., Palinski W., Witztum J. (La Jolla and Research Triangle Park, USA)	22
10.30	PPAR-gamma: LESSONS FROM GENETICS O'Rahilly S. , Chatterjee V.K.K. (Cambridge, UK)	22
11.00	<i>Break</i>	
11.30	ARE THIAZOLIDINEDIONES SUPERIOR TO STANDARD THERAPY IN THE TREATMENT OF TYPE 2 DIABETES? Taskinen M.-R. (Helsinki, Finland)	22
12.00	<i>End of the Session</i>	

Workshop

CLINICAL STUDIES WITH PPAR LIGANDS

Chairpersons: **Hamsten A.** (Stockholm, Sweden)
Franceschini G. (Milan, Italy)

hour:		abstract bk. page ref.:
14.00	FIBRATE TREATMENT TO RETARD PROGRESSION OF CORONARY ATHEROSCLEROSIS Hamsten A. (Stockholm, Sweden)	23
14.20	PPAR-gamma LIGANDS AND INTESTINAL INFLAMMATION Flanigan A., Judge T.A., Lewis J.D., Stein R.J., Lichtenstein G.R. Deren J.J., Arifaddin R., Murthy S., Wu G.D. (Philadelphia, USA)	23
14.40	PPAR-gamma: AN EMERGING THERAPEUTIC TARGET IN DERMATOLOGY Kurtz T.W. (San Francisco, USA)	23
15.00	INFLAMMATORY MECHANISMS IN ALZHEIMER'S DISEASE: beta-AMYLOID- STIMULATED PROINFLAMMATORY RESPONSES ARE BLOCKED BY PPAR-gamma AGONISTS Landreth G. , Combs C., Karlo C., Sundararajan S. (Cleveland, USA)	23
15.20	INCREASED TNF-ALPHA PRODUCTION EX VIVO IS ASSOCIATED WITH ELEVATED CRP AND FIBRINOGEN LEVELS IN HYPERTRIGLYCERIDEMIA. REVERSAL UPON LIPID-LOWERING THERAPY BY BEZAFIBRATE Jonkers I.J.A.M. , Mohrschladt M.F.M., de Man F.H.A.F., van der Laarse A., Smelt A.H.M. (Leiden, The Netherlands)	24
15.35	INSULIN SENSITIVITY AND APOLIPOPROTEIN A1 AND B CONCENTRATION CHANGES IN DYSLIPIDEMIC PATIENTS WITH METABOLIC SYNDROME AFTER FENOFIBRATE TREATMENT Idzior-Walus B. , Sieradzki J., Kawalec E. (Kraków, Poland)	24
15.50	EFFECTS OF FENOFIBRATE ON REVERSE CHOLESTEROL TRANSPORT IN HYPOALPHALIPOPROTEINEMIA Villa B. , Calabresi L., Bernini F., Sirtori C.R., Franceschini G. (Milan and Parma, Italy)	24
16.05	<i>End of the Session</i>	

Workshop

GENETICS OF PPARs

Chairperson: **Flavell D.M.** (London, UK)
Crestani M. (Milan, Italy)

hour:		abstract bk. page ref.:
14.00	THE PPAR-alpha GENE REGULATES LEFT VENTRICULAR GROWTH IN RESPONSE TO EXERCISE TRAINING Flavell D.M. , Jamshidi Y., World M., Montgomery H.E., Humphries S.E. (London and Hampshire, UK)	24
14.15	PPARs IN HEALTHY SUBJECTS AND TYPE II DIABETICS Sapone A. , Ciavarella A., Trespidi S., Paolini M., Biagi G.L., Cantelli-Forti G. (Bologna, Italy)	25
14.30	THE PRO12ALA POLYMORPHISM OF THE PPAR-gamma2 IS NOT ASSOCIATED WITH TYPE 2 DIABETES Ek J. , Andersen G., Urhammer S.A., Borch-Johnsen K., Hansen T., Pedersen O. (Gentofte and Glostrup, Denmark)	25
14.45	THE PPAR-gamma2 PRO12ALA VARIANT: ASSOCIATION WITH TYPE 2 DIABETES, TRAIT DIFFERENCES, AND INTERACTION WITH THE beta ₃ -ADRENERGIC RECEPTOR Tuomilehto J. , Douglas J.A., Erdos M.R., Watanabe R.M., Braun A., Oeth P., Mohlke K., Valle T., Ehnholm C., Buchanan T.A., Bergman R.N., Collins F.S., Boehnke M. (Helsinki, Finland, Ann Arbor, Bethesda, San Diego and Los Angeles, USA)	25
15.00	PREVALENCE OF PPAR-gamma-VARIANTS IN PATIENTS WITH INSULIN RESISTANCE, OBESITY AND IMPAIRED GLUCOSE TOLERANCE OR DIABETES MELLITUS AND CORONARY HEART DISEASE Blüher M., Klemm T., Paschke R. (Leipzig, Germany)	25
15.15	SUBCUTANEOUS ADIPOSE TISSUE FUNCTION IN A SUBJECT WITH A DOMINANT NEGATIVE PPAR-gamma MUTATION (PPAR-gammaP467L) Tan G.D. , Savage D., Frayn K.N., O'Rahilly S., Karpe F. (Oxford and Cambridge, UK)	26
15.30	THE PRO12ALA POLYMORPHISM IN PPARgamma2 IS ASSOCIATED WITH LOWER LIPOPROTEIN LIPASE ACTIVITY <i>IN VIVO</i> AND GREATER EXTENT OF CORONARY ARTERY DISEASE Schneider J., Schmidt N., Brandauer K., Kreuzer J., Dugi K.A. (Heidelberg, Germany)	26
15.45	A COMMON POLYMORPHISM IN EXON 4 OF THE PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR delta (PPAR-delta) GENE INFLUENCES THE PLASMA LDL LEVELS Skogsberg J. , Eriksson P., Hamsten A., Ehrenborg E. (Stockholm, Sweden)	26
16.00	<i>End of the Session</i>	